Age-specific survival of women with endometrioid adenocarcinoma of the uterus

被引:35
作者
Farley, JH
Nycum, LR
Birrer, MJ
Park, RC
Taylor, RR
机构
[1] Tripler Army Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Honolulu, HI 96859 USA
[2] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[3] NCI, Div Clin Sci, Med Branch, Cell & Canc Biol Dept, Rockville, MD 20850 USA
[4] Gynecol Oncol Grp, Philadelphia, PA USA
[5] St Barnabas Med Ctr, Livingston, NJ 07039 USA
关键词
age; survival; endometrial; cancer;
D O I
10.1006/gyno.2000.5934
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The purpose of this paper was to evaluate the age-specific survival for women diagnosed with endometrioid adenocarcinoma of the uterus. Methods. A retrospective analysis was conducted of 328 patients diagnosed with endometrioid adenocarcinoma of the uterus between January 1990 and December 1997. Patients were followed for 3 to 96 months with a mean of 43 months. The impact of age on survival was assessed using Col proportional hazard regression and multivariate analysis for age, stage, and grade. Stage and grade were analyzed using log-rank tests, and survival curves were generated by the Kaplan-Meier method. Results. A total of 328 patients were evaluated. Multivariate analysis revealed age, stage, and grade were all significant independent predictors of survival (P < 0.0001). Age-specific survival varied from a high of 90% at age 40 to a low of 55% at age 80. interval age-specific survival decreased below 86% at age 50. Subset analysis of patients younger than 50 compared with older patients revealed no difference in surgical stage or grade of tumors among these patients. Patients older than 50, however, were 41% more likely to receive adjuvant radiation therapy. Conclusion. Age is a specific, significant predictor of outcome in endometrioid adenocarcinoma of the uterus. Survival decreases significantly in patients older than 50. This decreased survival associated with age is unrelated to surgical stage or grade of adenocarcinoma, Decreased survival could involve molecular differences in the developing endometrial cancer or an increased risk of death from other non-cancer-related factors, (C) 2000 Academic Press.
引用
收藏
页码:86 / 89
页数:4
相关论文
共 28 条
[1]  
AALDERS J, 1980, OBSTET GYNECOL, V56, P419
[2]  
CHRISTOPHERSON WM, 1983, CANCER-AM CANCER SOC, V51, P1705, DOI 10.1002/1097-0142(19830501)51:9<1705::AID-CNCR2820510924>3.0.CO
[3]  
2-C
[4]  
CONNELLY PJ, 1982, OBSTET GYNECOL, V59, P569
[5]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[6]  
2-8
[7]  
CRISSMAN JD, 1981, OBSTET GYNECOL, V57, P699
[8]  
DOCKERTY M, 1951, AM J OBSTET GYNECOL, P966
[9]  
EICHNER E, 1971, OBSTET GYNECOL, V38, P739
[10]  
GAL D, 1983, AM J OBSTET GYNECOL, V146, P36